Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat
Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chose...
Saved in:
Published in | Advanced pharmaceutical bulletin Vol. 13; no. 3; pp. 521 - 531 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Tabriz
Tabriz University of Medical Sciences
01.07.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 2228-5881 2251-7308 |
DOI | 10.34172/apb.2023.054 |
Cover
Abstract | Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography. Results: Castor oil, Cremophor RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension. Conclusions: SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug. |
---|---|
AbstractList | This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.PurposeThis study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.MethodsThe suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.Castor oil, Cremophor® RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.ResultsCastor oil, Cremophor® RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.ConclusionSMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Many drugs are constantly administered orally, and it is also one of the most cost-effective systems for production besides all advantages reported for it.1,2 Oral absorption greatly depends on the dissolution rate in the gastric fluids.3 Most of the drugs have poor water-solubility and hence poor bioavailability as a major challenge for oral delivery.4,5 This poor bioavailability resulted from the fact that a drug cannot be absorbed from the gastrointestinal tract until it becomes soluble in gastric fluid.6,7 The rate-limiting step for absorption of poorly soluble but easily permeable drugs belonging to class II of the biopharmaceutics classification system is their solubility in gastric fluids.8 Resveratrol is a water-insoluble,(aqueous solubility =0.03 mg/mL) class II drug which, as an antioxidant polyphenol, exists in grapes, peanuts, and berries.9 This drug has been the subject of interest in recent years because of its anticancer, anti-aging, anti-diabetic, and cardio-protective effects.1013 The low bioavailability of resveratrol following oral administration is due to its low solubility.14,15 Novel drug delivery systems are capable of enhancing the pharmacokinetic properties and bioavailability of the drug through different strategies.16 Micro- and nano-emulsions are promising systems for the delivery of hydrophobic drugs.17 Furthermore, one of the popular novel drug delivery systems is the self-microemulsifying drug delivery system (SMEDDS) which is an isotropic mixture of oil, surfactant, and co-surfactant.18 When the formulation is faced with gastric fluids, it is rapidly converted to an oil-in-water emulsion by gentle movements of gastrointestinal muscles, hence called self-emulsifying.19,20 SMEDDS promotes drug absorption by increasing the amount of drug dissolved in the intestinal fluid. To determine the most suitable components, according to the standard method,23 an excess amount of resveratrol was dissolved in 2 mL of different vehicles including castor oil, pomegranate seed oil, grape seed oil, liquid paraffin, olive oil, medium-chain triglyceride, soybean oil, glycerol, ethyl oleate, sesame oil, and sunflower oil as the candidates for oil phase, and PEG,"", PEG,"", PEGm", PEG,m", and PG as 1 zUU 4UU 6UU 1SUU co-surfactants, and tween 20, tween 80, and Cremophor RH60 as surfactants. [...]samples were visually inspected for instability, and the size changes were evaluated by a zeta-sizer. Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography. Results: Castor oil, Cremophor RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension. Conclusions: SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug. |
Author | Mirzaeei, Shahla Islambulchilar, Ziba Tahmasebi, Negar |
AuthorAffiliation | 2 Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran 3 Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran 4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran 1 Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran |
AuthorAffiliation_xml | – name: 1 Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran – name: 3 Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran – name: 2 Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran – name: 4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran |
Author_xml | – sequence: 1 givenname: Shahla orcidid: 0000-0002-1132-3150 surname: Mirzaeei fullname: Mirzaeei, Shahla organization: Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran – sequence: 2 givenname: Negar orcidid: 0000-0001-6396-1456 surname: Tahmasebi fullname: Tahmasebi, Negar organization: Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran – sequence: 3 givenname: Ziba orcidid: 0000-0001-7037-4436 surname: Islambulchilar fullname: Islambulchilar, Ziba organization: Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran |
BookMark | eNptkkFvFCEYhiemJta1R-8kXjw4KwPMwHgxTa26ySZrWj0Thvlml4aBEZgm67_xn8ruVpM2XoDA-z7wfbwvizPnHRTF6wovKas4ea-mbkkwoUtcs2fFOSF1VXKKxdlhTURZC1G9KC5iNB1mjBNRtdV58XszJTOaXyoZ75AfkEK3YIdyNDp4GGcbzbA3bos-hTkPYM09hD263ccEIxp8QJugLLrsR-NMTOEfJ-0Arc3kp52xRh_t79ANxGxXKXj7AV27nXIaerRyCWIyLnO-QRhBddmS9sg4dKPSq-L5oGyEi4d5Ufz4fP396mu53nxZXV2uS83qNpXNoDEjmoASQrGGKMxbSkWNVYV5VQNv-0GLrmcN4IbyrheN6JXqKOe0VYLSRbE6cXuv7uQUzKjCXnpl5HHDh61UIRltQWaErhRpOoUFEz3tAKuOUaxbDkPPRWZ9PLGmuRuh1-ByZ-wj6OMTZ3Zy6-9lhVmDRdVkwtsHQvA_59weOZqowVrlwM9RElGLtmWHIhfFmyfSOz-H3M2DijHc8IayrKInVf7XGAMMUpt0_K38AGPzzfKYI5lzJA85kjlH2VU-cf2t4f_6Pw93z3M |
CitedBy_id | crossref_primary_10_1080_20415990_2024_2363635 crossref_primary_10_2147_IJN_S472287 crossref_primary_10_1007_s12247_025_09924_3 crossref_primary_10_2174_2211738511666230112123235 |
ContentType | Journal Article |
Copyright | 2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 The Authors. 2023 The Authors. 2023 |
Copyright_xml | – notice: 2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 The Authors. – notice: 2023 The Authors. 2023 |
DBID | AAYXX CITATION 8AO ABUWG AFKRA AZQEC BENPR CCPQU CWDGH DWQXO PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.34172/apb.2023.054 |
DatabaseName | CrossRef ProQuest Pharma Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Middle East & Africa Database ProQuest Central Korea Proquest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central Middle East & Africa Database ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2251-7308 |
EndPage | 531 |
ExternalDocumentID | oai_doaj_org_article_6e0c1a26ba0848d3be0ab430c97efd78 PMC10460816 10_34172_apb_2023_054 |
Genre | General Information |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GroupedDBID | 5VS 8AO AAYXX ABDBF ABUWG ACUHS ADBBV AEGXH AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ CCPQU CITATION CWDGH DIK EOJEC GROUPED_DOAJ GX1 HYE KQ8 OBODZ OK1 PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TUS AZQEC DWQXO PKEHL PQEST PQUKI 7X8 M~E 5PM PUEGO |
ID | FETCH-LOGICAL-c459t-6fc042c2ea88a462a07933850a10715e79dfc8bd46e0637bd868daab37739a833 |
IEDL.DBID | BENPR |
ISSN | 2228-5881 |
IngestDate | Wed Aug 27 00:56:19 EDT 2025 Thu Aug 21 18:36:26 EDT 2025 Mon Jul 21 10:28:02 EDT 2025 Mon Jun 30 03:17:04 EDT 2025 Tue Jul 01 04:25:25 EDT 2025 Thu Apr 24 23:10:46 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459t-6fc042c2ea88a462a07933850a10715e79dfc8bd46e0637bd868daab37739a833 |
Notes | SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-6396-1456 0000-0002-1132-3150 0000-0001-7037-4436 |
OpenAccessLink | https://www.proquest.com/docview/2844067634?pq-origsite=%requestingapplication% |
PQID | 2844067634 |
PQPubID | 2032008 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6e0c1a26ba0848d3be0ab430c97efd78 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460816 proquest_miscellaneous_2858994079 proquest_journals_2844067634 crossref_citationtrail_10_34172_apb_2023_054 crossref_primary_10_34172_apb_2023_054 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20230701 |
PublicationDateYYYYMMDD | 2023-07-01 |
PublicationDate_xml | – month: 07 year: 2023 text: 20230701 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Tabriz |
PublicationPlace_xml | – name: Tabriz |
PublicationTitle | Advanced pharmaceutical bulletin |
PublicationYear | 2023 |
Publisher | Tabriz University of Medical Sciences |
Publisher_xml | – name: Tabriz University of Medical Sciences |
SSID | ssib044728191 ssj0000603415 |
Score | 2.28262 |
Snippet | Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to... According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Many drugs are constantly... This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 521 |
SubjectTerms | antioxidant Antioxidants Bioavailability Design of experiments Drug delivery systems Drugs intestinal permeability Microemulsions Oral administration oral drug delivery Permeability Polyethylene glycol resveratrol self-micro emulsifying drug delivery systems single-pass intestinal perfusion Software Surfactants Vegetable oils |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQT7FQKiOhPW1aJ3YchxuPVhUCuiqt1Jvlp7pSNlntA2l_Tv8pM0m63RwQFy452E5ie8bjGXvmG0I-xJjmjouQZLnniYjKJcYUZQI7twMNNTph8Ub3x095fi2-3eQ3e6m-0CesgwfuJu5EBuZSk0lrEPndcxuYsYIzVxYh-qIN82Ul2zOmgJOEKPCCKN2dtjDJQFyjPyOeeCS5UmkHuAmlRXZiFvYY84gfs1wMNqgWx3-gfA5dJ_f2orOn5EmvRNJPXeefkUehfk7G0w6FejuhVw9BVasJHdPpAz719gW5uwAxMe_jL2kTqaG_QhWTOfrmhfmmWs3a4Cf6dbmBR6jQdWNLO2xzCkouvVji3wewu_gd0CXp99miWeAhjWtfn9DLsPqNwM3LpvpIT-vb1uOA4kEkCBccxRT2htChhW_prKaXZv2SXJ-dXn05T_pMDYkTeblOgKaw-F0WjFJGyMwg7B5XOTNgXaZ5KEofnbJeADUlL6xXUnljLC8KXhrF-StyUDd1eE2osE4EJYXxIgrBI4LnZNZ4ixG0TtoRmdyTR7sexhyzaVQazJmWmhqoqZGaGqg5IuNd80WH3_G3hp-R1rtGCLvdFgAz6p4Z9b-YcUQO7zlF97JgpUEBAK0J5Dj84_2uGlYxXs2YOjQbbJOD4QvGdTkiasBhgw4Na-rZbYsHjtf0mD_lzf8YwlvyGKek80g-JAfr5Sa8A71rbY_aJfYHFmot-A priority: 102 providerName: Directory of Open Access Journals |
Title | Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat |
URI | https://www.proquest.com/docview/2844067634 https://www.proquest.com/docview/2858994079 https://pubmed.ncbi.nlm.nih.gov/PMC10460816 https://doaj.org/article/6e0c1a26ba0848d3be0ab430c97efd78 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5Be-GCeApDqRYJ5RS3fqztdS-IQqoK0TYKrdSbtS-3kRzb2EmlXPgv_FNm7E2CD3DxwV6_NLPfzM7MfkPIxzz3IxUy4waRDl2Wc-UKkaQuWG4FHmqumMSM7sVlfH7Dvt1Gtzbg1tqyyg0mdkCtK4Ux8mOAUbA9MBvYp_qni12jMLtqW2g8JvsAwRz0fP90cjmdbTSKsQQTRf426uLFHsA21jVi5MONOPd74k04mwTHopZH2E_8yIvYwFB1fP4DJ3RYQvmXTTp7Rp5aZ5J-7qX_nDwy5QsymvZs1Osxvd5trmrHdESnO57q9Uvy-wrgYmH3YdIqp4L-MEXuLrBGzyxWRTvvNkHRr80KDqbAEo417TnOKTi79KrBtw_od_E54FPS7_O6qjFYo7rbx3Rm2gckcG6q4oROyvuu8oBiQBJABv9iCjbC9Kzhazov6UwsX5Gbs8n1l3PXdmxwFYvSpQuyBRBQgRGcCxYHAun3Qh55AlaZfmSSVOeKS81iA65RIjWPuRZChkkSpoKH4WuyV1aleUMok4oZHjOhWc5YmCOJTiCFlriTVsXSIeONeDJl6cyxq0aRwbKmk2YG0sxQmhlI0yGj7fC65_H418BTlPV2ENJvdyeq5i6zszmDz1e-CGIpsB2BDqXxhGShp9LE5DrhDjnYaEpmMaHNdhrskA_byzCbMUUjSlOtcEwEC2BYZKcO4QMNG3zQ8Eo5v-94wTFdj31U3v7_7e_IE_zZvub4gOwtm5V5D57VUh7a6XPYRSbgePFr8gemmihA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V6QEuiKcIFFgkyClu_VjbaySEKE2V0jSNQir1ZnbXuzRSYoc8QP45_AF-IzN-JPgAt158sNfetWZ2XjvzDSFvjHF85TFtuX7iWcxwZQkRRhZobgUWqlFM4onuxTDoX7HP1_71Hvld18JgWmUtEwtBnWQKY-RHIEZB98BuYB8W3y3sGoWnq3ULjZItznX-E1y21fuzE6DvW9c97U0-9a2qq4ClmB-tLZgfGFW5WnAuWOAKhIjzuG8L8IQcX4dRYhSXCQs0qO9QJjzgiRDSC0MvEhwDoCDy9xlWtLbI_nFvOBrXHMxYiAdTzjbKYwc2qAnMo8RIi-Vz7pRAn3A3dI_EQh5i__JD22cNxVj0D2gYvc2Uzb904Ol9cq8yXunHktsekD2dPiSdUYl-nXfpZFfMterSDh3tcLHzR-TXJYineVX3STNDBf2iZ8aaY06gnm9mq2lRdEVPlhu46BmmjOS0xFSnYFzTyyXO3oD7xe-ADUsH00W2wOCQKl7v0rFe_UDA6GU2e0d76U2R6UAxAApCDf9iBDpJlyjlOZ2mdCzWj8nVrdDyCWmlWaqfEsqkYpoHTCTMMOYZBO1xpUgkVu6qQLZJtyZPrCr4dOziMYvBjSqoGQM1Y6RmDNRsk852-KLEDfnXwGOk9XYQwn0XN7Llt7iSHjEsXznCDaTA9geJJ7UtJPNsFYXaJCFvk4OaU-JKBq3i3Y5pk9fbxyA98EhIpDrb4BgfHG5w6qM24Q0Oayyo-SSd3hQ45JgegH1bnv1_9lfkTn9yMYgHZ8Pz5-Qu_niZ73xAWuvlRr8Aq24tX1ZbiZKvt717_wDeZWIn |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqYS4IJ4iUGCRIKe4cey1vUZCiJJELS2pFVqpN3d3vUsjJXaIE1B-Dn-DX8eMHwk-wK2XHOx1vNa8Z2e-IeSNMX1PuUxbjpe4FjNcWUIEoQWWW4GHahSTeKL7ZewfX7LPV97VHvld98JgWWWtEwtFnWQKc-Q9UKNge0AaWM9UZRHRYPRh8d3CCVJ40lqP0yhZ5FRvfkL4lr8_GQCt3zrOaHjx6diqJgxYinnhyoK9ANMqRwvOBfMdgXBxLvdsAVFR39NBmBjFZcJ8DaY8kAn3eSKEdIPADQXHZCio__0AdsZaZP9oOI4mNTczFuAhVX-b8bF9G0wG1lRi1sXyOO-XoJ9wNXB6YiEPcZb5oe2xhpEsZgk0HOBm-eZf9nB0n9yrHFn6seS8B2RPpw9JJyqRsDdderFr7Mq7tEOjHUb25hH5dQ6qal71gNLMUEG_6pmx5lgfqOfrWT4tGrDoYLmGHz3D8pENLfHVKTja9HyJb29A_-L_gD9Lz6aLbIGJIlU83qUTnf9A8OhlNntHh-lNUfVAMRkKCg6_IgL7pEvE8g2dpnQiVo_J5a3Q8glppVmqnxLKpGKa-0wkzDDmGgTwcaRIJHbxKl-2SbcmT6wqKHWc6DGLIaQqqBkDNWOkZgzUbJPOdvmixBD518IjpPV2EUJ_Fxey5be40iQxbF_1heNLgaMQEldqW0jm2ioMtEkC3iYHNafElT7K4530tMnr7W3QJHg8JFKdrXGNB8E3BPhhm_AGhzU21LyTTm8KTHIsFcAZLs_-__ZX5A5IbXx2Mj59Tu7id5elzwektVqu9Qtw8FbyZSVJlFzftvD-ASLiZlM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimization+of+a+Self-microemulsifying+Drug+Delivery+System+for+Oral+Administration+of+the+Lipophilic+Drug%2C+Resveratrol%3A+Enhanced+Intestinal+Permeability+in+Rat&rft.jtitle=Advanced+pharmaceutical+bulletin&rft.au=Mirzaeei%2C+Shahla&rft.au=Tahmasebi%2C+Negar&rft.au=Islambulchilar%2C+Ziba&rft.date=2023-07-01&rft.issn=2228-5881&rft.eissn=2251-7308&rft.volume=13&rft.issue=3&rft.spage=521&rft.epage=531&rft_id=info:doi/10.34172%2Fapb.2023.054&rft.externalDBID=n%2Fa&rft.externalDocID=10_34172_apb_2023_054 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2228-5881&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2228-5881&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2228-5881&client=summon |